Drug Profile


Alternative Names: AKCEA-APO(a)-LRx; IONIS-APO(a)-LRx; ISIS 681257; ISIS-APO(a)-LRx; ISIS-APOALRx

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals
  • Class Antihyperlipidaemics; Antisense oligonucleotides
  • Mechanism of Action Apolipoprotein A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperlipoproteinaemias

Most Recent Events

  • 06 Jan 2017 Ionis Pharmaceuticals, Akcea Therapeutics and Novartis enter into an optional licensing agreement to co-promote and co-develop AKCEA APO(a) LRx for Hyperlipoproteinaemia
  • 21 Jun 2016 Phase-II clinical trials in Hyperlipoproteinaemia in Canada (SC) (Ionis Pharmaceuticals pipeline, June 2016)
  • 01 Feb 2016 Ionis completes a phase I trial in Hyperlipoproteinaemia in Canada (SC) (NCT02414594)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top